Figure 5.

19-CAR-ML NK cells have antigen-specific persistence in vivo. (A) Schema of in vivo studies. Briefly, NSG mice received 1 × 10⁶ Raji cells IV on day −3 followed by 3 × 10⁶ to 5 × 10⁶ 19-CAR-ML NK or 33-CAR-ML NK cells IV on day 0. Mice were euthanized on day 18, and human NK (hNK; mCD45⁻hCD45⁺CD56⁺) cells in the spleen and blood were assessed. (B) Representative bivariate plots at day 18 after transfer showing 19-CAR-ML (green) or 33-CAR-ML (red) NK cells in the blood. (C) Representative bivariate plots at day 18 after transfer showing 19-CAR-ML (green) or 33-CAR-ML (red) NK cells in the spleen, gated as in panel B. (D) Summary of data demonstrating the percentages of GFP⁺ NK cells in each organ. Data are from 2 experiment with n = 5 mice per group represented as mean ± SEM, compared using paired Student t test. *P < .05.